Leukemia News

The novel antimetabolite aspacytarabine appeared safe and efficacious as first-line therapy for patients with acute myeloid leukemia unfit for intensive chemotherapy, according to a study presented during the virtual ASCO Annual Meeting.

Ninety-five percent of patients with relapsed or refractory T-cell acute lymphoblastic leukemia responded to therapy with donor-derived chimeric antigen receptor T cells, according to results of a phase 1 study.

Acalabrutinib proved noninferior to ibrutinib in terms of PFS and resulted in less cardiotoxicity and fewer discontinuations due to adverse effects in a head-to-head trial among patients with previously treated chronic lymphocytic leukemia.

Brexucabtagene autoleucel induced an overall remission rate of greater than 70% among adults with relapsed or refractory B-cell acute lymphoblastic leukemia who received a single infusion of the therapy, according to phase 2 study results.

A novel chimeric antigen receptor T-cell therapy showed clinically relevant antitumor activity in nine of 11 younger patients with relapsed or refractory acute myeloid leukemia, according to early data from a phase 1/phase 2 study.

Ponatinib and blinatumomab induced high rates of complete molecular remission among patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, according to research presented during the virtual ASCO Annual Meeting.

Several researchers and global oncology leaders received ASCO’s Special Awards, the society’s highest honors.

Cheryl Willman, MD, has been named executive director of Mayo Clinic cancer programs.

The Leukemia & Lymphoma Society will collaborate with three major cancer centers to provide minority and other underserved populations with greater access to blood cancer clinical trials.

The FDA cleared an investigational new drug application for GDX012, a gamma-delta T-cell therapy, for patients with previously treated hematologic malignancies.